303 related articles for article (PubMed ID: 20049534)
1. Fatty acid oxidation disorders: outcome and long-term prognosis.
Wilcken B
J Inherit Metab Dis; 2010 Oct; 33(5):501-6. PubMed ID: 20049534
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening.
Spiekerkoetter U
J Inherit Metab Dis; 2010 Oct; 33(5):527-32. PubMed ID: 20449660
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biochemical monitoring of patients with fatty acid oxidation disorders.
Lund AM; Skovby F; Vestergaard H; Christensen M; Christensen E
J Inherit Metab Dis; 2010 Oct; 33(5):495-500. PubMed ID: 20066495
[TBL] [Abstract][Full Text] [Related]
4. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting.
Lindner M; Hoffmann GF; Matern D
J Inherit Metab Dis; 2010 Oct; 33(5):521-6. PubMed ID: 20373143
[TBL] [Abstract][Full Text] [Related]
5. Clinical aspects of short-chain acyl-CoA dehydrogenase deficiency.
van Maldegem BT; Wanders RJ; Wijburg FA
J Inherit Metab Dis; 2010 Oct; 33(5):507-11. PubMed ID: 20429031
[TBL] [Abstract][Full Text] [Related]
6. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
Yamada K; Taketani T
J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
[TBL] [Abstract][Full Text] [Related]
7. Impact of newborn screening for fatty acid oxidation disorders on neurological outcome: A Belgian retrospective and multicentric study.
Everard E; Laeremans H; Boemer F; Marie S; Vincent MF; Dewulf JP; Debray FG; De Laet C; Nassogne MC
Eur J Paediatr Neurol; 2024 Mar; 49():60-65. PubMed ID: 38377647
[TBL] [Abstract][Full Text] [Related]
8. Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era.
Janeiro P; Jotta R; Ramos R; Florindo C; Ventura FV; Vilarinho L; Tavares de Almeida I; Gaspar A
Eur J Pediatr; 2019 Mar; 178(3):387-394. PubMed ID: 30617651
[TBL] [Abstract][Full Text] [Related]
9. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders.
Spiekerkoetter U; Bastin J; Gillingham M; Morris A; Wijburg F; Wilcken B
J Inherit Metab Dis; 2010 Oct; 33(5):555-61. PubMed ID: 20830526
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial fatty acid oxidation disorders: pathophysiological studies in mouse models.
Spiekerkoetter U; Wood PA
J Inherit Metab Dis; 2010 Oct; 33(5):539-46. PubMed ID: 20532823
[TBL] [Abstract][Full Text] [Related]
11. Update on mitochondrial fatty acid oxidation disorders.
Spiekerkoetter U; Mayatepek E
J Inherit Metab Dis; 2010 Oct; 33(5):467-8. PubMed ID: 20842433
[No Abstract] [Full Text] [Related]
12. The clinical manifestation of MCAD deficiency: challenges towards adulthood in the screened population.
Schatz UA; Ensenauer R
J Inherit Metab Dis; 2010 Oct; 33(5):513-20. PubMed ID: 20532824
[TBL] [Abstract][Full Text] [Related]
13. A heterozygous missense mutation in adolescent-onset very long-chain acyl-CoA dehydrogenase deficiency with exercise-induced rhabdomyolysis.
Hisahara S; Matsushita T; Furuyama H; Tajima G; Shigematsu Y; Imai T; Shimohama S
Tohoku J Exp Med; 2015 Apr; 235(4):305-10. PubMed ID: 25843429
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biochemical outcome of patients with very long-chain acyl-CoA dehydrogenase deficiency.
Rovelli V; Manzoni F; Viau K; Pasquali M; Longo N
Mol Genet Metab; 2019 May; 127(1):64-73. PubMed ID: 31031081
[TBL] [Abstract][Full Text] [Related]
15. Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians.
Potter BK; Little J; Chakraborty P; Kronick JB; Evans J; Frei J; Sutherland SC; Wilson K; Wilson BJ
J Inherit Metab Dis; 2012 Jan; 35(1):115-23. PubMed ID: 21630065
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients.
Vianey-Saban C; Divry P; Brivet M; Nada M; Zabot MT; Mathieu M; Roe C
Clin Chim Acta; 1998 Jan; 269(1):43-62. PubMed ID: 9498103
[TBL] [Abstract][Full Text] [Related]
17. New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency.
Stanley CA
Adv Pediatr; 1987; 34():59-88. PubMed ID: 3318304
[TBL] [Abstract][Full Text] [Related]
18. The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results.
Wanders RJ; Ruiter JP; IJLst L; Waterham HR; Houten SM
J Inherit Metab Dis; 2010 Oct; 33(5):479-94. PubMed ID: 20490924
[TBL] [Abstract][Full Text] [Related]
19. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening.
Kang E; Kim YM; Kang M; Heo SH; Kim GH; Choi IH; Choi JH; Yoo HW; Lee BH
BMC Pediatr; 2018 Mar; 18(1):103. PubMed ID: 29519241
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biochemical outcomes of patients with medium-chain acyl-CoA dehydrogenase deficiency.
Anderson DR; Viau K; Botto LD; Pasquali M; Longo N
Mol Genet Metab; 2020 Jan; 129(1):13-19. PubMed ID: 31836396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
